Page last updated: 2024-12-07

n(6)-phenyladenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

N(6)-phenyladenosine is a synthetic adenosine analog that has been shown to have a variety of biological activities, including anti-inflammatory, analgesic, and neuroprotective effects. It is believed to exert its effects by acting as an agonist of the adenosine A2A receptor. N(6)-phenyladenosine has been studied as a potential treatment for a number of diseases, including Parkinson's disease, Alzheimer's disease, and stroke.'

Cross-References

ID SourceID
PubMed CID101430
CHEMBL ID262083
CHEBI ID112766
SCHEMBL ID1050156
MeSH IDM0053038

Synonyms (29)

Synonym
MLS002153269
MLS001074192
PDSP2_001010
PDSP1_001026
23589-16-4
n6-phenyladenosine
MLS000069355 ,
smr000058677
NCGC00023481-03
CHEBI:112766
NCGC00023481-04
CHEMBL262083
(2r,3r,4s,5r)-2-(6-anilinopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
nsc 517192
adenosine, n-phenyl-
n(6)-phenyladenosine
HMS2234O19
SCHEMBL1050156
(2r,3r,4s,5r)-2-(6-anilinopurin-9-yl)-5-methylol-tetrahydrofuran-3,4-diol
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-phenylazanylpurin-9-yl)oxolane-3,4-diol
bdbm42467
cid_101430
(2r,3r,4s,5r)-2-(6-anilino-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol
OPERA_ID_298
Q27192995
REGID_FOR_CID_101430
DTXSID801017208
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-(phenylamino)-9h-purin-9-yl)tetrahydrofuran-3,4-diol
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(phenylamino)-9h-purin-9-yl]oxolane-3,4-diol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
purine nucleoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (32)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency37.93300.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency7.22820.01846.806014.1254AID624172; AID743262
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.50120.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency13.83520.004110.890331.5287AID493106; AID504466; AID504467
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624146
ParkinHomo sapiens (human)Potency14.58100.819914.830644.6684AID720573
P53Homo sapiens (human)Potency35.48130.07319.685831.6228AID504706
arylsulfatase AHomo sapiens (human)Potency0.03011.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency25.11890.035520.977089.1251AID504332
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency9.06460.01262.451825.0177AID485313
vasopressin V1b receptorHomo sapiens (human)Potency30.88100.194416.018043.6206AID492948
chromobox protein homolog 1Homo sapiens (human)Potency0.00600.006026.168889.1251AID488953
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency25.92900.00419.984825.9290AID504444
huntingtin isoform 2Homo sapiens (human)Potency2.51190.000618.41981,122.0200AID1688
ras-related protein Rab-9AHomo sapiens (human)Potency8.27170.00022.621531.4954AID485297
gemininHomo sapiens (human)Potency0.10320.004611.374133.4983AID624296
relaxin receptor 1 isoform 1Homo sapiens (human)Potency8.33480.038814.350143.6206AID2676; AID489012
relaxin receptor 2 isoform 1Homo sapiens (human)Potency17.36570.048815.980148.9431AID489043
lamin isoform A-delta10Homo sapiens (human)Potency0.04470.891312.067628.1838AID1487
TAR DNA-binding protein 43Homo sapiens (human)Potency31.62281.778316.208135.4813AID652104
Ataxin-2Homo sapiens (human)Potency3.54810.011912.222168.7989AID588378
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.75690.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
neuropeptide Y receptor type 1Homo sapiens (human)IC50 (µMol)7.82601.93806.50679.0040AID1279
neuropeptide Y receptor type 2Homo sapiens (human)IC50 (µMol)4.72900.22004.49478.1510AID1272
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)0.00490.00020.552110.0000AID30337; AID31412
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki0.00510.00011.20929.9700AID31849; AID32015; AID32176; AID32179; AID32324; AID32361; AID32479; AID32502
Adenosine receptor A2bRattus norvegicus (Norway rat)IC50 (µMol)0.66000.00240.68169.0000AID30819
Adenosine receptor A2bRattus norvegicus (Norway rat)Ki25.60000.00061.353610.0000AID33726; AID33901
Adenosine receptor A2aRattus norvegicus (Norway rat)IC50 (µMol)0.66000.00120.48289.0000AID30819
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki25.60000.00021.494010.0000AID33726; AID33901
Adenosine receptor A1Gallus gallus (chicken)IC50 (µMol)0.00460.00250.00800.0170AID31835
Equilibrative nucleoside transporter 1Homo sapiens (human)IC50 (µMol)32.35940.00013.688363.0000AID330912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A2aHomo sapiens (human)Affinity constant50.00000.20006.028610.0000AID33909
Adenosine receptor A2bHomo sapiens (human)Affinity constant50.00000.20006.028610.0000AID33909
Adenosine receptor A2bRattus norvegicus (Norway rat)Ratio0.66300.00330.82929.6000AID33745
Adenosine receptor A1Homo sapiens (human)Affinity constant0.00300.00301.069110.0000AID30353
Adenosine receptor A2aRattus norvegicus (Norway rat)Ratio0.66300.00330.82309.6000AID33745
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (150)

Processvia Protein(s)Taxonomy
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
positive regulation of chronic inflammatory response to non-antigenic stimulusAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A2bHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
positive regulation of chemokine productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of interleukin-6 productionAdenosine receptor A2bHomo sapiens (human)
mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
positive regulation of mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
relaxation of vascular associated smooth muscleAdenosine receptor A2bHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2bHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
vasodilationAdenosine receptor A2bHomo sapiens (human)
temperature homeostasisAdenosine receptor A1Homo sapiens (human)
response to hypoxiaAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processAdenosine receptor A1Homo sapiens (human)
negative regulation of acute inflammatory responseAdenosine receptor A1Homo sapiens (human)
negative regulation of leukocyte migrationAdenosine receptor A1Homo sapiens (human)
positive regulation of peptide secretionAdenosine receptor A1Homo sapiens (human)
positive regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
negative regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
regulation of glomerular filtrationAdenosine receptor A1Homo sapiens (human)
protein targeting to membraneAdenosine receptor A1Homo sapiens (human)
phagocytosisAdenosine receptor A1Homo sapiens (human)
inflammatory responseAdenosine receptor A1Homo sapiens (human)
signal transductionAdenosine receptor A1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
cell-cell signalingAdenosine receptor A1Homo sapiens (human)
nervous system developmentAdenosine receptor A1Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A1Homo sapiens (human)
response to inorganic substanceAdenosine receptor A1Homo sapiens (human)
negative regulation of glutamate secretionAdenosine receptor A1Homo sapiens (human)
response to purine-containing compoundAdenosine receptor A1Homo sapiens (human)
lipid catabolic processAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicAdenosine receptor A1Homo sapiens (human)
positive regulation of nucleoside transportAdenosine receptor A1Homo sapiens (human)
negative regulation of neurotrophin productionAdenosine receptor A1Homo sapiens (human)
positive regulation of protein dephosphorylationAdenosine receptor A1Homo sapiens (human)
vasodilationAdenosine receptor A1Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, non-REM sleepAdenosine receptor A1Homo sapiens (human)
negative regulation of apoptotic processAdenosine receptor A1Homo sapiens (human)
positive regulation of potassium ion transportAdenosine receptor A1Homo sapiens (human)
positive regulation of MAPK cascadeAdenosine receptor A1Homo sapiens (human)
negative regulation of hormone secretionAdenosine receptor A1Homo sapiens (human)
cognitionAdenosine receptor A1Homo sapiens (human)
leukocyte migrationAdenosine receptor A1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
positive regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
regulation of sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergicAdenosine receptor A1Homo sapiens (human)
fatty acid homeostasisAdenosine receptor A1Homo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A1Homo sapiens (human)
long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
mucus secretionAdenosine receptor A1Homo sapiens (human)
negative regulation of mucus secretionAdenosine receptor A1Homo sapiens (human)
triglyceride homeostasisAdenosine receptor A1Homo sapiens (human)
regulation of cardiac muscle cell contractionAdenosine receptor A1Homo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic potentiationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Gallus gallus (chicken)
G protein-coupled receptor signaling pathwayAdenosine receptor A1Gallus gallus (chicken)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
neurotransmitter uptakeEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleobase-containing compound metabolic processEquilibrative nucleoside transporter 1Homo sapiens (human)
xenobiotic metabolic processEquilibrative nucleoside transporter 1Homo sapiens (human)
neurotransmitter transportEquilibrative nucleoside transporter 1Homo sapiens (human)
xenobiotic transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
lactationEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleobase transportEquilibrative nucleoside transporter 1Homo sapiens (human)
adenine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleoside transportEquilibrative nucleoside transporter 1Homo sapiens (human)
purine nucleoside transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
cytidine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
uridine transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
adenosine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
inosine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
hypoxanthine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
thymine transportEquilibrative nucleoside transporter 1Homo sapiens (human)
excitatory postsynaptic potentialEquilibrative nucleoside transporter 1Homo sapiens (human)
cellular response to glucose stimulusEquilibrative nucleoside transporter 1Homo sapiens (human)
cellular response to hypoxiaEquilibrative nucleoside transporter 1Homo sapiens (human)
pyrimidine-containing compound transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
transport across blood-brain barrierEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleoside transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
guanine transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
uracil transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
pyrimidine nucleobase transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
purine nucleobase transmembrane transportEquilibrative nucleoside transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2bHomo sapiens (human)
protein bindingAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor activityAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor bindingAdenosine receptor A1Homo sapiens (human)
purine nucleoside bindingAdenosine receptor A1Homo sapiens (human)
protein bindingAdenosine receptor A1Homo sapiens (human)
heat shock protein bindingAdenosine receptor A1Homo sapiens (human)
G-protein beta/gamma-subunit complex bindingAdenosine receptor A1Homo sapiens (human)
heterotrimeric G-protein bindingAdenosine receptor A1Homo sapiens (human)
protein heterodimerization activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
G protein-coupled adenosine receptor activityAdenosine receptor A1Gallus gallus (chicken)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
neurotransmitter transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
nucleoside transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
adenine transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
guanine transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
uracil transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
purine nucleoside transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
cytidine transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
uridine transmembrane transporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
pyrimidine- and adenosine-specific:sodium symporter activityEquilibrative nucleoside transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (36)

Processvia Protein(s)Taxonomy
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A2bHomo sapiens (human)
presynapseAdenosine receptor A2bHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
basolateral plasma membraneAdenosine receptor A1Homo sapiens (human)
axolemmaAdenosine receptor A1Homo sapiens (human)
asymmetric synapseAdenosine receptor A1Homo sapiens (human)
presynaptic membraneAdenosine receptor A1Homo sapiens (human)
neuronal cell bodyAdenosine receptor A1Homo sapiens (human)
terminal boutonAdenosine receptor A1Homo sapiens (human)
dendritic spineAdenosine receptor A1Homo sapiens (human)
calyx of HeldAdenosine receptor A1Homo sapiens (human)
postsynaptic membraneAdenosine receptor A1Homo sapiens (human)
presynaptic active zoneAdenosine receptor A1Homo sapiens (human)
synapseAdenosine receptor A1Homo sapiens (human)
dendriteAdenosine receptor A1Homo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
plasma membraneAdenosine receptor A1Gallus gallus (chicken)
synapseAdenosine receptor A1Gallus gallus (chicken)
dendriteAdenosine receptor A1Gallus gallus (chicken)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
plasma membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
basolateral plasma membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
apical plasma membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
presynapseEquilibrative nucleoside transporter 1Homo sapiens (human)
postsynapseEquilibrative nucleoside transporter 1Homo sapiens (human)
plasma membraneEquilibrative nucleoside transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (81)

Assay IDTitleYearJournalArticle
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID32015Binding affinity to adenosine A1 receptor in rat whole brain membranes by [3H]N6-cyclohexyladenosine displacement.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID330859Agonist activity human adenosine A2B receptor expressed in CHO cells assessed as stimulation of adenylate cyclase relative to NECA2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Probing distal regions of the A2B adenosine receptor by quantitative structure-activity relationship modeling of known and novel agonists.
AID1293509Antiviral activity against Enterovirus 71 infected in human RD cells assessed as cell viability after 3 days by MTS assay2016European journal of medicinal chemistry, Mar-23, Volume: 111Modification of the length and structure of the linker of N(6)-benzyladenosine modulates its selective antiviral activity against enterovirus 71.
AID32781Effective concentration against A2AR mediated P12 adenylatencyclase activity1991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.
AID340155Antitumor activity against human HT29 cells after 48 hrs by MTS assay2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID32179Inhibition of [3H]- (R)-P1A binding to adenosine A1 receptor1991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.
AID1452128Inhibition of ATPgammaS-BODIPY binding to Thermotoga maritima His-tagged HK853 expressed in Escherichia coli BL21(DE3)pLysS Rosetta preincubated for 30 mins prior to ATPgammaS-BODIPY addition measured after 1 hr by coomassie staining-based SDS-PAGE analys2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Rational Design of Selective Adenine-Based Scaffolds for Inactivation of Bacterial Histidine Kinases.
AID235175Relative affinities for adenosine A2 and A1 receptors1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
N6-phenyladenosines: pronounced effect of phenyl substituents on affinity for A2 adenosine receptors.
AID32641Selectivity as ratio of Ki for binding to adenosine A1 and A2 receptors1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists.
AID30496Molar potency ratio (MPR) against adenosine A2 receptor of canine coronary artery1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Dog coronary artery adenosine receptor: structure of the N6-aryl subregion.
AID30353Affinity constant for inhibition of A1 receptor control of adenylate cyclase in adipocytes, heart and brain cells1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID32324Inhibition of [3H]-CHA binding to rat brain membrane Adenosine A1 receptor1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors.
AID330912Binding affinity to ENT1 transporter2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity.
AID30491Binding affinity against A2 adenosine receptor1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Dog coronary artery adenosine receptor: structure of the N6-aryl subregion.
AID33591Binding of Adenosine A2 receptor in whole rat brain membrane using [3H]CHA as a Radioligand1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors.
AID31849Affinity for adenosine A1 receptor at rat cortical receptors using 1 nM [3H]PIA1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists.
AID340156Antitumor activity against human MCF7 cells after 48 hrs by MTS assay2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID33901Inhibition of [3H]- NECA binding to adenosine receptor A21991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.
AID9803Association constant against A2 adenosine receptor1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Dog coronary artery adenosine receptor: structure of the N6-aryl subregion.
AID33909Affinity constant for A2 receptor control of adenylate cyclase in adipocytes, heart and brain cells1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID232726Selectivity ratio of compounds 10a and 10b against A2 receptor1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists.
AID340153Antitumor activity against human K562 cells after 48 hrs by MTS assay2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID32479Binding affinity for Adenosine A1 receptor in corpora striata of rats using [3H]NECA1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID33726Binding affinity for Adenosine A2 receptor in corpora striata of rats using [3H]NECA1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID34160Inhibition of Adenylate Cyclase in Rat adipocytes1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors.
AID340154Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID33903Ratio of binding potencies at adenosine A2AR and AIAR receptors1991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.
AID1293511Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus 712016European journal of medicinal chemistry, Mar-23, Volume: 111Modification of the length and structure of the linker of N(6)-benzyladenosine modulates its selective antiviral activity against enterovirus 71.
AID33567Binding affinity to A2 adenosine receptor in rat striatal membranes by [3H]NECA (1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-beta-D-ribofuranuronamide) displacement.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID330858Agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as stimulation of adenylate cyclase2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Probing distal regions of the A2B adenosine receptor by quantitative structure-activity relationship modeling of known and novel agonists.
AID232321Ratio of adenosine A2 to A1 receptor binding1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID32176Binding affinity for Adenosine A1 receptor using [3H]- CHA or [3H]- PIA1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID30819Displacement of [3H]-NECA from adenosine A2 receptor of rat striatal membrane1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
N6-phenyladenosines: pronounced effect of phenyl substituents on affinity for A2 adenosine receptors.
AID131362Effect on Ataxia in mouse following i.p. administration.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID30337Evaluated for binding affinity against Adenosine A1 receptor1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
A steric and electrostatic comparison of three models for the agonist/antagonist binding site on the adenosine A1 receptor.
AID1293510Cytotoxicity against human RD cells2016European journal of medicinal chemistry, Mar-23, Volume: 111Modification of the length and structure of the linker of N(6)-benzyladenosine modulates its selective antiviral activity against enterovirus 71.
AID131363Effect on Motor activity in mouse following i.p. administration.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID31412Evaluated for the binding affinity towards the Adenosine A1 receptor in cerebral cortices of Sprague-Dawley male rats using [3H]CHA as radioligand.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID25506Index of hydrophobicity (k')1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Dog coronary artery adenosine receptor: structure of the N6-aryl subregion.
AID34158Inhibition of adenyl cyclase via P site in adipocytes; Inactive1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID232725Selectivity ratio of compounds 10a and 10b against A1 receptor1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists.
AID30499Acidic dissociation constant(pKa) against A2 adenosine receptor of coronary artery1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Dog coronary artery adenosine receptor: structure of the N6-aryl subregion.
AID32502Inhibition of binding of 1 nM N6-[3H]cyclohexyladenosine to adenosine A1 receptor on rat cerebral cortical membranes.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Functionalized congeners of adenosine: preparation of analogues with high affinity for A1-adenosine receptors.
AID31835Displacement of [125I]ABA from adenosine A1 receptor of chick cerebellar membrane1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
N6-phenyladenosines: pronounced effect of phenyl substituents on affinity for A2 adenosine receptors.
AID32361Evaluated for the binding affinity towards the Adenosine A1 receptor in corpora striata of rats using [3H]CHA as radioligand.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID33745Binding affinity for Adenosine A2 receptor using [3H]- NECA1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID33429Affinity for adenosine A2 receptor at rat striatal membrane using 5 nM [3H]CGS-216801992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (21.43)18.7374
1990's6 (21.43)18.2507
2000's6 (21.43)29.6817
2010's7 (25.00)24.3611
2020's3 (10.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.18 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]